Extended Safety Study of Tenofovir Disoproxil Fumarate (TDF) Among HIV-1 Negative Men

This study is ongoing, but not recruiting participants.
Information provided by Centers for Disease Control and Prevention

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			HIV Infection
2		Additional conditions recognized in this trial
			Acquired Immunodeficiency Syndrome
			HIV Infections
			Infection
3		More general conditions related to this trial
			Immune System Diseases
			Immunologic Deficiency Syndromes
			Lentivirus Infections
			Retroviridae Infections
			RNA Virus Infections
			Sexually Transmitted Diseases
			Sexually Transmitted Diseases, Viral
			Slow Virus Diseases
			Virus Diseases
4		Interventions listed in this trial
			Daily oral tenofovir
5		Additional drug interventions recognized in this trial
			Tenofovir
			Tenofovir disoproxil
6		More general drug interventions related to this trial
			Anti-HIV Agents
			Anti-Infective Agents
			Anti-Retroviral Agents
			Antiviral Agents
			Enzyme Inhibitors
			Molecular Mechanisms of Pharmacological Action
			Nucleic Acid Synthesis Inhibitors
			Pharmacologic Actions
			Reverse Transcriptase Inhibitors
			Therapeutic Uses
7		Sponsors listed in this trial
			Centers for Disease Control and Prevention
			San Francisco Department of Public Health
			AIDS Research Consortium of Atlanta